Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Evon Poon, … , Charles Y. Lin, Louis Chesler
Evon Poon, … , Charles Y. Lin, Louis Chesler
Published October 5, 2020
Citation Information: J Clin Invest. 2020;130(11):5875-5892. https://doi.org/10.1172/JCI134132.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 18

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

  • Text
  • PDF
Abstract

The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively targeted MYCN-amplified neuroblastoma via multiple mechanisms. CDK9 — a component of the transcription elongation complex P-TEFb — bound to the MYCN-amplicon superenhancer, and its inhibition resulted in selective loss of nascent MYCN transcription. MYCN loss led to growth arrest, sensitizing cells for apoptosis following CDK2 inhibition. In MYCN-amplified neuroblastoma, MYCN invaded active enhancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively reversed by CYC065. MYCN overexpression in mesenchymal neuroblastoma was sufficient to induce adrenergic identity and sensitize cells to CYC065. CYC065, used together with temozolomide, a reference therapy for relapsed neuroblastoma, caused long-term suppression of neuroblastoma growth in vivo, highlighting the clinical potential of CDK9/2 inhibition in the treatment of MYCN-amplified neuroblastoma.

Authors

Evon Poon, Tong Liang, Yann Jamin, Susanne Walz, Colin Kwok, Anne Hakkert, Karen Barker, Zuzanna Urban, Khin Thway, Rhamy Zeid, Albert Hallsworth, Gary Box, Marli E. Ebus, Marco P. Licciardello, Yordan Sbirkov, Glori Lazaro, Elizabeth Calton, Barbara M. Costa, Melanie Valenti, Alexis De Haven Brandon, Hannah Webber, Nicolas Tardif, Gilberto S. Almeida, Rossitza Christova, Gunther Boysen, Mark W. Richards, Giuseppe Barone, Anthony Ford, Richard Bayliss, Paul A. Clarke, Johann De Bono, Nathanael S. Gray, Julian Blagg, Simon P. Robinson, Suzanne A. Eccles, Daniella Zheleva, James E. Bradner, Jan Molenaar, Igor Vivanco, Martin Eilers, Paul Workman, Charles Y. Lin, Louis Chesler

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2009 Total
Citations: 3 5 9 12 10 1 40
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (40)

Title and authors Publication Year
T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma
Maggi E, Landolina N, Munari E, Mariotti FR, Tumino N, Vacca P, Azzarone B, Moretta L
Frontiers in Immunology 2025
ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma
Lorenzi F, Jostes S, Gao Q, Hutchinson JC, Tall J, Martins da Costa B, Cooke AJ, Rampling D, Ogunbiyi O, Barker K, Hughes D, Barone G, Barisa M, Bellini A, Hubank M, Schleiermacher G, Anderson J, Bernstein E, Chesler L, George SL
Cancer letters 2025
Response of GEM models of neuroblastoma to cabozantinib assessed by multiparametric magnetic resonance imaging
Almeida GS, King P, Hallsworth A, Webber H, Popov S, Miranda S, Yogev O, Pearson AD, Chesler L, Jamin Y, Robinson SP
Neoplasia (New York, N.Y.) 2025
The MYCN 5′ UTR as a therapeutic target in neuroblastoma
Volegova MP, Brown LE, Banerjee U, Dries R, Sharma B, Kennedy A, Porco JA Jr, George RE
Cell Reports 2024
Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Hawash M
Cells 2024
CDK9 inhibitors for the treatment of solid tumors.
Mo C, Wei N, Li T, Ahmed Bhat M, Mohammadi M, Kuang C, Mo C, Wei N, Li T, Ahmed Bhat M, Mohammadi M, Kuang C
Biochemical pharmacology 2024
Targeting CDK2 to combat drug resistance in cancer therapy
Kasirzadeh S, Lenjisa JL, Wang S
Future Oncology 2024
Wilms tumor primary cultures capture phenotypic heterogeneity and facilitate preclinical screening
Götz L, Wegert J, Paikari A, Appenzeller S, Bausenwein S, Vokuhl C, Treger TD, Drost J, Linderkamp C, Schneider DT, Ernestus K, Warman SW, Fuchs J, Welter N, Graf N, Behjati S, Furtwängler R, Gessler M
Translational Oncology 2024
Antagonistic effect of cyclin-dependent kinases and a calcium-dependent phosphatase on polyglutamine-expanded androgen receptor toxic gain of function
Piol D, Tosatto L, Zuccaro E, Anderson EN, Falconieri A, Polanco MJ, Marchioretti C, Lia F, White J, Bregolin E, Minervini G, Parodi S, Salvatella X, Arrigoni G, Ballabio A, La Spada AR, Tosatto SC, Sambataro F, Medina DL, Pandey UB, Basso M, Pennuto M
Science Advances 2023
A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle
Li HL, Dong LL, Jin MJ, Li QY, Wang X, Jia MQ, Song J, Zhang SY, Yuan S
Molecules (Basel, Switzerland) 2023
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
Candido MF, Medeiros M, Veronez LC, Bastos D, Oliveira KL, Pezuk JA, Valera ET, Brassesco MS
Pharmaceutics 2023
P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway
Wang Z, Mačáková M, Bugai A, Kuznetsov SG, Hassinen A, Lenasi T, Potdar S, Friedel CC, Barborič M
Nucleic Acids Research 2023
The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma
Wang D, Yin Z, Wang H, Wang L, Li T, Xiao R, Xie T, Han R, Dong R, Liu H, Liang K, Qing G
Science Advances 2023
Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
Xiao L, Liu Y, Chen H, Shen L
Cancer biology & therapy 2023
TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
Zhang X, Zhan S, Guan X, Zhang Y, Lu J, Yu Y, Jin Y, Yang Y, Chu P, Hong E, Yang H, Ren H, Geng D, Wang Y, Zhou P, Guo Y, Chang Y
Cancer Science 2023
Targeting Myc-driven stress addiction in colorectal cancer
Saeed H, Leibowitz BJ, Zhang L, Yu J
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2023
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
Soosainathan A, Iravani M, El-Botty R, Alexander J, Sourd L, Morisset L, Painsec P, Orha R, Nikitorowicz-Buniak J, Pancholi S, Haider S, Dowsett M, Marangoni E, Martin LA, Isacke CM
Cancer research 2023
Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma
A Nijhuis, A Sikka, O Yogev, L Herendi, C Balcells, Y Ma, E Poon, C Eckold, G Valbuena, Y Xu, Y Liu, B da Costa, M Gruet, C Wickremesinghe, A Benito, H Kramer, A Montoya, D Carling, E Want, Y Jamin, L Chesler, H Keun
Nature Communications 2022
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells
R Chen, Y Chen, P Xiong, D Zheleva, D Blake, M Keating, W Wierda, W Plunkett
Leukemia 2022
Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL -deficiency allows for selective targeting of clear cell renal cell carcinoma
L Nelson, K Castro, B Xu, J Li, N Dinh, J Thompson, J Woytash, K Kipp, O Razorenova
Cell cycle (Georgetown, Tex.) 2022
TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
H Wang, X Wang, L Xu, J Zhang
2022
Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
Shendy NA, Zimmerman MW, Abraham BJ, Durbin AD
Cell reports. Medicine 2022
CDK9 inhibitors in cancer research
Huang Z, Wang T, Wang C, Fan Y
2022
Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells
Pandey S, Djibo R, Darracq A, Calendo G, Zhang H, Henry RA, Andrews AJ, Baylin SB, Madzo J, Najmanovich R, Issa JP, Raynal NJ
Cancers 2022
Immunotherapy of Neuroblastoma: Facts and Hopes
Anderson J, Majzner RG, Sondel PM
Clinical cancer research 2022
Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
van der Noord VE, van de Water B, Le Dévédec SE
Cancers 2022
IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells
Xu X, Cui J, Wang H, Ma L, Zhang X, Guo W, Xue X, Wang Y, Qiu S, Tian X, Miao Y, Wu M, Yu Y, Xu Y, Wang J, Qiao Y
2022
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
Jia SQ, Zhuo R, Zhang ZM, Yang Y, Tao YF, Wang JW, Li XL, Xie Y, Li G, Wu D, Chen YL, Yu JJ, Feng CX, Li ZH, Zhou RF, Yang RD, Yang PC, Zhou B, Wan XM, Wu YM, Jiao WY, Zhou NN, Fang F, Pan J
Journal of Immunology Research 2022
Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent
Yang J, Davidoff AM
Cancers 2022
Targeting cyclin-dependent kinase 9 in cancer therapy
Y Shen, Y Wang, Y Zhang, S Ma, L Yang, C Zhao, X Huang
Acta Pharmacologica Sinica 2021
Targeting MYCN in Pediatric and Adult Cancers
Z Liu, SS Chen, S Clarke, V Veschi, CJ Thiele
Frontiers in Oncology 2021
Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead
S Shrestha, A Morcavallo, C Gorrini, L Chesler
Frontiers in Oncology 2021
Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs
R Ciaccio, PD Rosa, S Aloisi, M Viggiano, L Cimadom, SK Zadran, G Perini, G Milazzo
International journal of molecular sciences 2021
Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy
Y Zhou, X Gao, M Yuan, B Yang, Q He, J Cao
Frontiers in pharmacology 2021
Molecular Mechanisms of MYCN Dysregulation in Cancers
R Liu, P Shi, Z Wang, C Yuan, H Cui
Frontiers in Oncology 2021
Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis
TT Liu, R Li, C Huo, JP Li, J Yao, X Ji, YQ Qu
Frontiers in Cell and Developmental Biology 2021
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
E Panagiotou, G Gomatou, IP Trontzas, N Syrigos, E Kotteas
Clinical and Translational Oncology 2021
Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation
V Juric, L Hudson, J Fay, CE Richards, H Jahns, M Verreault, F Bielle, A Idbaih, ML Lamfers, AM Hopkins, M Rehm, BM Murphy
Cell Death and Disease 2021
The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme
Urban-Wójciuk Z, Graham A, Barker K, Kwok C, Sbirkov Y, Howell L, Campbell J, Woster PM, Poon E, Petrie K, Chesler L
Cancer Gene Therapy 2021
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Posted by 8 X users
Referenced in 1 patents
71 readers on Mendeley
See more details